Apex Healthcare Consulting

is the MD and founder of Apex Healthcare Consulting. After completing his PhD at Southampton and carrying out post-doctoral research at NorthWestern University, Chicago, he joined the industry first in clinical research and later in project management at Glaxo Laboratories. After completing an MBA in 1993, David joined the International Business Analysis team in Glaxo Holdings, where he spent five years carrying out a variety of strategic projects. In this role he was responsible for commercial analysis and evaluation for a number of international therapy teams most notably working on Zantac for over five years. After leaving GlaxoWellcome in 1996 David established Praxis Research and Consulting with two colleagues, as one of the founding directors. The company focused mainly on market research and in 1998 spun off the consultancy arm so forming an independent group – Apex Healthcare Consulting. In the ten years since Apex began the partnership has grown to ten employees and upwards of ten associates.

is a Project Director at Apex Healthcare Consulting. After completing a BSc at Queen’s University Belfast, Diane joined the pharmaceutical industry in 1987. She spent over nine years as a protein biochemist in drug discovery with SmithKline Beecham, leading research projects in a number of different therapy areas. Diane joined the drug development company, Vanguard Medica (now Vernalis), as Project Evaluation Manager in 1997, where she was responsible for the scientific evaluation of in-licensing opportunities. In 1999 she led the technical due diligence team in the merger of Vanguard Medica with Cerebrus. From 2000 onwards, Diane became Director of Business Development at Vernalis, during which time she managed the technical and commercial aspects of licensing and business development activities in EU, USA and Japan. From 2003, Diane has been a Project Director at Apex Healthcare Consulting, working on a range of due diligence and business development projects for both established and start-up companies and for private equity firms.

has a broad range of strategic and corporate planning experience gained in both the pharmaceutical and oil industries. On graduating from Durham University, Neroli joined Mobil Oil Co. and worked six years, initially in Marketing Services and then in Strategic Planning. Following her MBA at City University Business School, Neroli spent six years with Glaxo, firstly as Strategic Planning Manager for Glaxo Pharmaceuticals UK and then as Business Planning Manager for Glaxo Holdings. In this role, Neroli worked directly with the main board on a wide range of corporate planning projects including portfolio development and acquisition assessment. After leaving Glaxo in 1993, Neroli worked for eight years as a consultant in the Strategic Consulting Division of Parexel Medical Marketing Services Ltd, where she helped global pharmaceutical companies with scenario planning, strategy development, and market analysis.

has recently joined Apex Healthcare Consulting as a Project Director. After completing a BSc in Biochemistry at the University of St Andrews, Alex joined the Financial Times as a company writer focusing on the healthcare sector. His key responsibilities were making investment recommendations, writing new and feature articles, and building industry contacts. In 2004 Alex joined Wood Mackenzie as a senior analyst focusing on events and trends that shape the pharmaceutical and biotechnology sector. The key responsibilities were corporate analysis, therapy area analysis, forecasting, product development reviews and supporting a range of consulting projects.